The High Court of Karnataka has formally quashed criminal proceedings initiated against the pharmaceutical retail chain MedPlus and its directors, bringing an end to a protracted legal dispute involving an alleged overcharge of ₹1.12. In an order delivered on November 13, 2026, Justice S Vishwajith Shetty determined that the prosecution, which centered on a minor supply discrepancy involving a single tablet, failed to meet the essential criteria for an offense under the Drugs (Price Control) Order, 2013, and the Essential Commodities Act, 1955.

The litigation originated from a private complaint filed by the Assistant Drugs Controller of Bengaluru, following an incident on August 23, 2016, involving a purchase made by a senior reporter with a regional media outlet. The complainant alleged that while the pharmacy had generated a bill for eight tablets of Lanzol Junior 15 mg at a cost of ₹40.32, the actual quantity provided at the point of sale was limited to seven tablets. Consequently, the complaint contended that the pharmacy had collected an excess amount of ₹1.12, thereby contravening established price control regulations.

Following this incident, criminal proceedings were registered under Clause 26 of the Drugs (Price Control) Order, 2013, read in conjunction with Section 7(1)(a)(ii) and Section 11 of the Essential Commodities Act, 1955. The case moved through the procedural stages, eventually resulting in the accused filing petitions under Section 482 of the Code of Criminal Procedure (Cr.P.C.) before the High Court of Karnataka to seek the quashing of the entire case pending before the Court of the III Additional Chief Metropolitan Magistrate in Bengaluru.

Judicial Interpretation of Price Control Regulations

In reviewing the legal merits of the case, the High Court focused on the specific language governing the pricing of pharmaceutical formulations. The court highlighted the clear constraints defined under the regulatory framework, noting: "No person shall sell any formulation to any consumer at a price exceeding the price specified in the current price list or price indicated on the label of the container or pack thereof, whichever is less."

Justice Shetty emphasized that the statutory provision is intended to prevent vendors from charging above the maximum retail price (MRP) or the notified ceiling price of a drug. Upon examining the facts presented, the court found that the prosecution's narrative did not align with the definition of the offense. The court noted: "In the case on hand, the allegation against the accused is that they had supplied 7 tablets instead of 8 tablets and they had collected excess amount of Rs.1.12 from the complainant."

Crucially, the court observed that the core of the prosecution’s argument rested on a quantitative shortfall in supply, rather than the charging of a price that exceeded the prescribed legal limits for the medication itself. Because the pricing of the tablets did not breach the ceiling price mandated by the Drugs (Price Control) Order, the invocation of criminal statutes was viewed by the bench as an overreach.

Addressing the Abuse of Legal Process

The ruling highlights the judiciary’s role in ensuring that criminal law is not utilized in matters involving trivial disputes that do not demonstrate a clear violation of public policy or consumer safety. By allowing the petitions filed by MedPlus and its officials—including directors P. Srinivas and M. Surendranath, as well as staff members Sudhakar Reddy and Rangaswamy K—the High Court underscored the importance of distinguishing between operational administrative errors and criminal offenses.

The court articulated a stern view on the unnecessary burden placed upon the accused throughout the legal process. Justice Shetty stated: "I am of the opinion that prosecution of the petitioners for the aforesaid offences would not only cause embarassment to them, but would also amount to abuse of process of law ." By characterizing the continued pursuit of the case as an abuse of process, the High Court signaled that judicial resources should be reserved for matters involving substantive breaches of law rather than minor transactional errors.

The decision effectively serves as a shield for corporate entities and individual practitioners against litigation predicated on disproportionate responses to singular, non-systemic incidents. This outcome provides much-needed clarity for retailers operating within the complex landscape of pharmaceutical regulations, reinforcing that liability for price manipulation requires evidence of intentional or systemic overcharging above the permitted price ceiling, rather than isolated supply discrepancies.

The operative direction of the court was clear and immediate: all proceedings in C.C. No. 7712/2019, which had been pending before the III Additional Chief Metropolitan Magistrate in Bengaluru, stand quashed in their entirety. The accused are relieved of the requirement to continue their defense against these specific charges, bringing a definitive close to a case that had persisted for nearly a decade since the initial complaint was filed in August 2016. The judgment serves as a reminder of the necessity for regulatory authorities to maintain proportionality in the enforcement of consumer protection laws, ensuring that legal proceedings remain focused on significant violations that threaten public welfare.